Your browser doesn't support javascript.
loading
Using Biomarkers to Predict Memantine Effects in Alzheimer's Disease: A Proposal and Proof-Of-Concept Demonstration.
Swerdlow, Neal R; Kotz, Juliana E; Joshi, Yash B; Talledo, Jo; Sprock, Joyce; Molina, Juan L; Huisa, Branko; Huege, Steven F; Romero, Jairo Alberto; Walsh, Michael J; Delano-Wood, Lisa; Light, Gregory A.
Afiliação
  • Swerdlow NR; Department of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA, USA.
  • Kotz JE; Department of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA, USA.
  • Joshi YB; Department of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA, USA.
  • Talledo J; VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, USA.
  • Sprock J; Department of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA, USA.
  • Molina JL; Department of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA, USA.
  • Huisa B; VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, USA.
  • Huege SF; Department of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA, USA.
  • Romero JA; VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, USA.
  • Walsh MJ; Department of Neurosciences, School of Medicine, University of California, San Diego, La Jolla, CA, USA.
  • Delano-Wood L; Department of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA, USA.
  • Light GA; Department of Medicine, School of Medicine, University of California, San Diego, La Jolla, CA, USA.
J Alzheimers Dis ; 84(4): 1431-1438, 2021.
Article em En | MEDLINE | ID: mdl-34690144
ABSTRACT
Memantine's benefits in Alzheimer's disease (AD) are modest and heterogeneous. We tested the feasibility of using sensitivity to acute memantine challenge to predict an individual's clinical response. Eight participants completed a double-blind challenge study of memantine (placebo versus 20 mg) effects on autonomic, subjective, cognitive, and neurophysiological measures, followed by a 24-week unblinded active-dose therapeutic trial (10 mg bid). Study participation was well tolerated. Subgroups based on memantine sensitivity on specific laboratory measures differed in their clinical response to memantine, some by large effect sizes. It appears feasible to use biomarkers to predict clinical sensitivity to memantine.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Biomarcadores / Memantina / Cognição / Antagonistas de Aminoácidos Excitatórios / Doença de Alzheimer Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Biomarcadores / Memantina / Cognição / Antagonistas de Aminoácidos Excitatórios / Doença de Alzheimer Idioma: En Ano de publicação: 2021 Tipo de documento: Article